Effect of metformin on exercise capacity in treatment naïve type 2 diabetes patients.

Q2 Pharmacology, Toxicology and Pharmaceutics

Drug metabolism and personalized therapy Pub Date : 2024-12-16 DOI:10.1515/dmpt-2024-0049

Vikneswaran Gunaseelan, Sandhiya Selvarajan, Sadishkumar Kamalanathan, Tamilarasu Kadhiravan, Shravan Venkatraman

{"title":"Effect of metformin on exercise capacity in treatment naïve type 2 diabetes patients.","authors":"Vikneswaran Gunaseelan, Sandhiya Selvarajan, Sadishkumar Kamalanathan, Tamilarasu Kadhiravan, Shravan Venkatraman","doi":"10.1515/dmpt-2024-0049","DOIUrl":null,"url":null,"abstract":"Objectives: Exercise capacity is decreased in diabetes mellitus due to impaired insulin sensitivity, endothelial dysfunction and mitochondrial dysfunction. The aim of the study was to evaluate the effect of metformin on exercise capacity in treatment naïve patients with type 2 diabetes mellitus.Methods: Newly diagnosed type 2 diabetes mellitus patients were tested for baseline insulin resistance and exercise capacity, before starting on metformin. Exercise capacity was measured by incremental exercise testing in treadmill (ZAN 600 CPET system) using modified Bruce protocol at baseline, 6 weeks and 12 weeks following metformin therapy.Results: A total of 33 treatment naïve type 2 diabetes patients were enrolled of which 19 patients completed the study. There was no significant change in any of the exercise capacity parameters at the end of 12 weeks of metformin. Nevertheless, there was a significant improvement in VO2/kg among those with insulin resistance as compared to those without insulin resistance.Conclusions: Metformin monotherapy did not produce any change in exercise capacity in treatment naïve type 2 diabetes patients. However, a significant fall in exercise capacity (VO2/kg) was observed in patients without insulin resistance as compared to those with insulin resistance at the end of 12 weeks of metformin therapy.","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug metabolism and personalized therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/dmpt-2024-0049","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Exercise capacity is decreased in diabetes mellitus due to impaired insulin sensitivity, endothelial dysfunction and mitochondrial dysfunction. The aim of the study was to evaluate the effect of metformin on exercise capacity in treatment naïve patients with type 2 diabetes mellitus.

Methods: Newly diagnosed type 2 diabetes mellitus patients were tested for baseline insulin resistance and exercise capacity, before starting on metformin. Exercise capacity was measured by incremental exercise testing in treadmill (ZAN 600 CPET system) using modified Bruce protocol at baseline, 6 weeks and 12 weeks following metformin therapy.

Results: A total of 33 treatment naïve type 2 diabetes patients were enrolled of which 19 patients completed the study. There was no significant change in any of the exercise capacity parameters at the end of 12 weeks of metformin. Nevertheless, there was a significant improvement in VO₂/kg among those with insulin resistance as compared to those without insulin resistance.

Conclusions: Metformin monotherapy did not produce any change in exercise capacity in treatment naïve type 2 diabetes patients. However, a significant fall in exercise capacity (VO₂/kg) was observed in patients without insulin resistance as compared to those with insulin resistance at the end of 12 weeks of metformin therapy.

查看原文本刊更多论文

二甲双胍对初次接受治疗的 2 型糖尿病患者运动能力的影响。

目的：由于胰岛素敏感性受损、内皮功能障碍和线粒体功能障碍，糖尿病患者的运动能力会下降。本研究旨在评估二甲双胍对新接受治疗的 2 型糖尿病患者运动能力的影响：方法：在开始服用二甲双胍之前，对新诊断的 2 型糖尿病患者进行基线胰岛素抵抗和运动能力测试。在二甲双胍治疗后的基线、6周和12周，采用改良布鲁斯方案在跑步机（ZAN 600 CPET系统）上进行增量运动测试，测量运动能力：共有 33 名刚接受治疗的 2 型糖尿病患者参加了研究，其中 19 名患者完成了研究。在服用二甲双胍 12 周后，运动能力参数均无明显变化。然而，与无胰岛素抵抗的患者相比，有胰岛素抵抗的患者的VO2/kg有明显改善：结论：二甲双胍单药治疗对刚接受治疗的2型糖尿病患者的运动能力没有任何影响。结论：二甲双胍单药治疗对刚接受治疗的 2 型糖尿病患者的运动能力没有任何影响，但在二甲双胍治疗 12 周结束时，观察到无胰岛素抵抗的患者的运动能力（VO2/kg）明显低于有胰岛素抵抗的患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug metabolism and personalized therapy Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)

CiteScore

2.30

自引率

0.00%

发文量

期刊介绍： Drug Metabolism and Personalized Therapy (DMPT) is a peer-reviewed journal, and is abstracted/indexed in relevant major Abstracting Services. It provides up-to-date research articles, reviews and opinion papers in the wide field of drug metabolism research, covering established, new and potential drugs, environmentally toxic chemicals, the mechanisms by which drugs may interact with each other and with biological systems, and the pharmacological and toxicological consequences of these interactions and drug metabolism and excretion. Topics: drug metabolizing enzymes, pharmacogenetics and pharmacogenomics, biochemical pharmacology, molecular pathology, clinical pharmacology, pharmacokinetics and drug-drug interactions, immunopharmacology, neuropsychopharmacology.